Novartis signs not-for-profit leprosy technology transfer deal with Brazil
This article was originally published in Scrip
Executive Summary
Novartis and the Brazilian government have signed a technology transfer deal that will see Brazil locally produce Lamprene (clofazimine) to treat leprosy for the national health system (SNS). The deal comes both as a means of controlling the disease in Brazil and as strengthening the local pharmaceutical industry to reduce the country's dependency on foreign suppliers.